Finance

Lists
EW:NYSE
Edwards Lifesciences Corp
US$ ८५.२१
+१.१०%
(+०.९३) 1D
US$ ८५.२१
०.००% (०.००)
After hours
Closed: अक्टोबर ९, १६:००:०५ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EW...
Open
US$ ८४.६०
High
US$ ८५.३४
Low
US$ ८३.२२
Mkt. cap
४९.१२ अरब
Avg. vol.
३४.२७ लाख
Volume
३८.९१ लाख
P/E ratio
४९.३०
52-wk high
US$ ९६.२९
52-wk low
US$ ७२.३०
EPS
US$ १.७३
Beta
०.८७
Shares outstanding
५७.६४ करोड
No. of employees
१६ हजार
Open
US$ ८४.६०
High
US$ ८५.३४
Low
US$ ८३.२२
Mkt. cap
४९.१२ अरब
Avg. vol.
३४.२७ लाख
Volume
३८.९१ लाख
P/E ratio
४९.३०
52-wk high
US$ ९६.२९
52-wk low
US$ ७२.३०
EPS
US$ १.७३
Beta
०.८७
Shares outstanding
५७.६४ करोड
No. of employees
१६ हजार
News stories
From web sources and news partners
Profile
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027. Wikipedia
About Edwards Lifesciences Corp
CEO-
Employees१६ हजार
Founded१९५८
Headquartersइरविन, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 16 analysts giving stock ratings to EW in the past 3 months
Strong buy
Buy
13
Hold
3
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for EW in the last 3 months.
Highest
Current US$ ८५.२१
US$ ११०.०० (+२९.०९%)
Average
US$ १०४.०० (+२२.०५%)
Lowest
US$ ८५.०० (-०.२५%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Wood
UBS
Buy
Maintained
US$ ११०.००
+२९.१%
10/07/2026
Matt Miksic
Barclays
Buy
Maintained
US$ ११०.००
+२९.१%
10/07/2026
Tycho Peterson
Jefferies
Buy
Initiated
US$ ११०.००
+२९.१%
10/07/2026
Joanne Wuensch
Citi
Buy
Maintained
US$ ११०.००
+२९.१%
10/05/2026
Kendall Au
RBC Capital
Buy
Maintained
US$ ११०.००
+२९.१%
10/01/2026
Mike Kratky
Leerink Partners
Buy
Reiterated
US$ १०१.००
+१८.५%
09/28/2026
Adam Maeder
Piper Sandler
Buy
Maintained
US$ १०१.००
+१८.५%
09/21/2026
Matthew Taylor
Jefferies
Buy
Maintained
US$ १०५.००
+२३.२%
09/11/2026
Marie Thibault
BTIG
Buy
Maintained
US$ ११०.००
+२९.१%
09/10/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
09/10/2026
William Plovanic
Canaccord Genuity
Hold
Maintained
US$ ८५.००
-०.२%
08/03/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
US$ १०५.००
+२३.२%
07/28/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
US$ ११०.००
+२९.१%
07/24/2026
Suraj Kalia
Oppenheimer
Hold
Maintained
-
-
07/24/2026
Richard Newitter
Truist Financial
Hold
Reiterated
US$ ९५.००
+११.५%
07/24/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
US$ ११०.००
+२९.१%
07/23/2026
Travis Steed
Bank of America Securities
Buy
Maintained
US$ १००.००
+१७.४%
07/21/2026
Josh Jennings
TD Cowen
Buy
Reiterated
US$ १०४.००
+२२.१%
07/23/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
US$ १०५.००
+२३.२%
07/15/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
US$ १००.००
+१७.४%
07/06/2026
David Roman
Goldman Sachs
Buy
Maintained
US$ ९८.००
+१५%
06/15/2026
Krish Sankar
TD Cowen
Buy
Reiterated
US$ १०४.००
+२२.१%
06/02/2026
David Toung
Argus Research
Buy
Maintained
-
-
05/21/2026
David Rescott
Robert W. Baird
Hold
Maintained
US$ ८७.००
+२.१%
04/24/2026
Michael Polark
Wolfe Research
Buy
Upgraded
US$ ९२.००
+८%
04/01/2026
Danielle Antalffy
UBS
Hold
Maintained
US$ ९०.००
+५.६%
02/12/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
US$ १००.००
+१७.४%
02/11/2026
Last report
२०२६ जुलाई २३
Fiscal period
Q2 2026
US$ ०.७८ / US$ ०.७४
+५.११%beat
Revenue / Est. (USD)
१.७४ अरब / १.७० अरब
+२.४४%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१.५५ अरब
१.५७ अरब
१.६५ अरब
१.७४ अरब
Cost of goods sold
३४.५२ करोड
३४.३० करोड
३६.२६ करोड
३९.२४ करोड
Cost of revenue
३४.५२ करोड
३४.३० करोड
३६.२६ करोड
३९.२४ करोड
Research and development expenses
२८.०७ करोड
२६.७७ करोड
२६.३३ करोड
२७.८९ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५१.४६ करोड
६०.१२ करोड
५२.२२ करोड
५६.१२ करोड
Operating expense
७८.२८ करोड
८५.४६ करोड
७७.१३ करोड
८२.९१ करोड
Total operating expenses
१.१३ अरब
१.२० अरब
१.१३ अरब
१.२२ अरब
Operating income
४२.५१ करोड
३७.२० करोड
५१.४७ करोड
५१.९५ करोड
Other non operating income
११.०० लाख
२३.०० लाख
६.९९ करोड
-२.५० करोड
EBT including unusual items
३४.८४ करोड
९.०४ करोड
४५.९० करोड
५१.९८ करोड
EBT excluding unusual items
४४.४५ करोड
४६.४० करोड
६०.३६ करोड
५१.११ करोड
Income tax expense
५.६१ करोड
२.६२ करोड
७.८३ करोड
२७.८४ करोड
Effective tax rate
१६.१०%
२८.९८%
१७.०६%
५३.५६%
Other operating expenses
-१.२५ करोड
-१.४३ करोड
-१.४२ करोड
-१.१० करोड
Net income
२९.११ करोड
९.१२ करोड
३८.०७ करोड
२४.१९ करोड
Net profit margin
१८.७४%
५.८१%
२३.०९%
१३.८९%
Earnings per share
०.६७
०.५८
०.७८
०.७८
Interest and investment income
१.६७ करोड
११.४२ करोड
१.७४ करोड
१.५० करोड
Interest expense
-
-२.०४ करोड
-
-
Net interest expenses
१.६७ करोड
९.३८ करोड
१.७४ करोड
१.५० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
४६.४३ करोड
४१.४७ करोड
५५.५६ करोड
५६.२२ करोड
Gain or loss from assets sale
-
-३.३९ करोड
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू